CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Texas
THIS AGREEMENT (“AGREEMENT”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“MDA”), a component institution of the SYSTEM and INTRON THERAPEUTICS, INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (“LICENSEE”).
CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Washington
This Exclusive License Agreement (this “Agreement”) is made as of this 19th day of July, 1999 (the “Effective Date”) by and between Introgen Therapeutics, Inc., a Texas corporation having its principal place of business at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (“Introgen”), Corixa Corporation, a Delaware corporation having its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104 (the “Company”), and Chinook Corporation, a Delaware corporation and a wholly-owned subsidiary of the Company (“Chinook,” and, collectively with the Company, “Corixa”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION NON-EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and P53 INC.Non-Exclusive License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • New Jersey
This Non-Exclusive License Agreement (this “Agreement”), effective as of the date of last signature hereto (the “Effective Date”), is entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey, having a place of business at One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey 08889 (“Merck”) and P53 INC., a corporation organized and existing under the laws of Delaware, having a place of business at 2000 Edwards Street, Houston, TX 77007 (“P53”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ASSET PURCHASE AGREEMENTAsset Purchase Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Texas
THIS ASSET PURCHASE AGREEMENT is made as of this 6th day of November, 2009, by and among INTROGEN THERAPEUTICS, INC., a Delaware corporation (“Introgen Therapeutics”) and INTROGEN TECHNICAL SERVICES, INC., a Delaware corporation (“Introgen Services”), as debtors and debtors-in-possession (each a “Seller” and together “Sellers”), and POPE INVESTMENTS II LLC, a Delaware limited liability company (“Buyer”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION FIRST AMENDMENT TO THE LICENSE AND EXCLUSIVE LICENSE OPTION AGREEMENTLicense Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations
This Amendment (“Amendment”) to the Exclusive License and License Option Agreement, (hereinafter, the “Agreement”), executed this 15th day of May 2012, is made and entered into by and between SAINT LOUIS UNIVERSITY, a Missouri nonprofit corporation (“University”) and VIRRX, INC, a Delaware corporation (“Licensee”). The effective date of this Amendment shall be May 15th, 2012.
AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Texas
This is AMENDMENT NO. 1 effective this 1st day of September, 1996, (“EFFECTIVE AMENDMENT NO. 1 DATE”) to the Patent and Technology License Agreement dated July 20, 1994 (hereinafter referred to as the “AGREEMENT”), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and INTROGEN THERAPEUTICS, INC,. located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”).
MULTIVIR, INC. CREDIT FACILITY AGREEMENTCredit Facility Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Delaware
This Credit Facility Agreement, dated effective as of December 4, 2014 (the “Effective Date”) is entered into by and among MultiVir, Inc., a Delaware corporation (the “Company”), and the Lender set forth on the signature page hereto (the “Lender”).
NOTE CONVERSION AGREEMENTNote Conversion Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Delaware
This NOTE CONVERSION AGREEMENT (the “Agreement”) is made as of December 4, 2014, by and between MultiVir, Inc., a Delaware corporation (the “Company”), and Pope Investments II, LLC (the “Investor”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION P53 Inc. Option Agreement MGH Case No. 1289 Agreement No. A216775Option Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Massachusetts
This Option Agreement (“Agreement”) is made and entered into as of the 28th day of May, 2013 (“Effective Date”) by and between P53 Inc., a Delaware corporation whose principal place of business is located at 2000 Edwards Street, Houston, TX 77007 (“Company”), and The General Hospital Corporation, a not-for-profit Massachusetts corporation, d/b/a Massachusetts General Hospital (“Hospital”), whose headquarters is located at Fruit Street, Boston, Massachusetts 02114 (each a “Party” and collectively, the “Parties”).
ContractPromissory Note • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Delaware
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. IT MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THIS NOTE MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 2 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Texas
This is AMENDMENT NO. 2 effective this 8 day of August, 1997, (“EFFECTIVE AMENDMENT NO. 2 DATE”) to the Patent and Technology License Agreement dated July 20, 1994, as amended by that certain Amendment No. 1 effective September 1, 1996 (HEREINAFTER REFERRED TO AS THE “FIRST AMENDED AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and INTROGEN THERAPEUTICS, INC., located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”).
MultiVir,Inc. (formerly P53 Inc.) Option Agreement Second Extension MGH Case No. 1289 Agreement No. A216775Option Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations
The parties to that certain Option Agreement effective as of May 28, 2013 extend by a first extension executed on or about May 28, 2014, hereby agree that pursuant to Article 1.2 therein, to extend the Option granted to p53, Inc., now known as MultiVir, Inc., a Delaware corporation, for a period of six months from November 28, 2014.
Technology Transfer OfficeLicense Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Missouri
This Agreement (the “Agreement”) is made effective as of this 1st day of March 2002 (“the Effective Date”) between the Saint Louis University, a nonprofit academic institution incorporated in the State of Missouri, having a business office located at Health Sciences Center, 3556 Caroline Street, Room C-110, St. Louis, Missouri 63104 (hereinafter “University”) and VirRx, Inc., a Delaware corporation, having its principal place of business at 1609 Adgers Wharf Drive, St. Louis, Missouri 63017 (hereinafter “Licensee”) (also referred to herein individually as the “Party” and collectively as the “Parties”).
ContractEvaluation Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • New Jersey
ContractExclusive License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Washington
This amendment corrects a technical error where the reference to Section 4.4 as set forth below was incorrectly 4.2 in the original document.
CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SECOND AMENDMENT TO THE AMENDED AND RESTATED RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • New York
This Amendment to the Amended and Restated Research and License Agreement, is hereinafter referred to as the “Second Amendment”.
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION P53 Inc. Option Agreement Extension MGH Case No. 1289 Agreement No. A216775Option Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations
The parties to that certain Option Agreement effective as of May 28th, 2013, hereby agree that pursuant to Article, 1.2 therein, to extend the Option granted to p53, Inc., now known as MultiVir, Inc., a Delaware corporation, for a period of six months from May 28, 2014. Accordingly, MultiVir’s Option shall expire on November 28, 2014.
CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION MASTER PRECLINICAL STUDY AGREEMENTMaster Preclinical Study Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Texas
This MASTER PRECLINICAL STUDY AGREEMENT (this “Master Agreement”) is effective March 6, 2008,(the “Effective Date”), between Introgen Therapeutics, Inc. (“Introgen”), and The University of Texas M. D. Anderson Cancer Center (“Institution”), a member institution of The University of Texas System (“System”). Based upon the Background below and in consideration of the mutual promises herein and the benefits hereunder, the parties agree as follows:
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION MILESTONE EXTENSION AGREEMENT COLUMBIA UNIVERSITY – CORIXA – CHINOOK – INTROGEN...Milestone Extension Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations
This Milestone Extension Agreement (the “Agreement”) is effective as of November 12, 2001, and is by and among: the Trustees of Columbia University in the City of New York, New York (“Columbia”); Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington 98104 (“Corixa”), the successor-in-interest to Chinook Corporation, 1124 Columbia Street, Suite 200, Seattle, Washington 98104 (prior to direct merger into Corixa effective in December, 2000, a wholly owned subsidiary of Corixa, and a successor by merger to GenQuest, Inc.) (“Chinook”); and Introgen Therapeutics, 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (“Introgen”).
SAINT LOUIS UNIVERSITY LABORATORY SERVICES AGREEMENTLaboratory Services Agreement • December 22nd, 2014 • MultiVir Inc. • Pharmaceutical preparations • Missouri
THIS LABORATORY SERVICES AGREEMENT (“Agreement”) is made effective as of December 3, 2012 (“Effective Date”) by and between VirRx, Inc., having a principal place of business at 1609 Adgers Wharf Drive (“Company”) and Saint Louis University, a Missouri benevolent corporation having its principal place of business located at 221 North Grand Boulevard, St. Louis, Missouri 63103 (“SLU” or “Laboratory”). Company and Laboratory are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
